Abstract
Background: Despite the therapeutic use of peptides is limited because of their metabolism in vivo, there are no systematic reviews explaining degradation of peptides by peptidases. This review summarizes peptidases present in the tissues and metabolic characteristics of peptides, and provides recent strategies for improving the metabolic stability of peptides.
Method: We reviewed a number of peptidases including their functional groups, tissue localization and cleavage specificity. Given the broad distribution of peptidases in the body, several tissues, such as the liver, kidney, lung, blood, nasal epithelial cells, placenta and skin, have the capacity to metabolize peptides. We compared the metabolic characteristics of peptides in these tissues and then summarized strategies for improving peptide stability.
Results: In addition to the primary organs including liver, kidney, gastrointestinal tract and blood involved in peptide metabolism, other organs such as the lung, skin, placenta and nasal mucosa may also play a role in peptide degradation. At present, the main measures to improve the stability of the peptide include N- and/or C-terminal modification or substitution, D-amino acid or unnatural amino acid substitution, cyclization, backbone modification, nanoparticle formulations and increased molecular mass.
Conclusion: This review summarized the key in vivo peptidases and their tissue distribution characteristics, and presented strategies to improve the metabolic stability and bioavailability of peptide drugs. These viewpoints will benefit the further development and utilization of peptide drugs.
Keywords: Peptides, peptidases, metabolism, stability, bioavailability, modification.
Current Drug Metabolism
Title:Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability
Volume: 19 Issue: 11
Author(s): Jin-Feng Yao, Hong Yang, Yan-Zhi Zhao and Ming Xue*
Affiliation:
- Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069,China
Keywords: Peptides, peptidases, metabolism, stability, bioavailability, modification.
Abstract: Background: Despite the therapeutic use of peptides is limited because of their metabolism in vivo, there are no systematic reviews explaining degradation of peptides by peptidases. This review summarizes peptidases present in the tissues and metabolic characteristics of peptides, and provides recent strategies for improving the metabolic stability of peptides.
Method: We reviewed a number of peptidases including their functional groups, tissue localization and cleavage specificity. Given the broad distribution of peptidases in the body, several tissues, such as the liver, kidney, lung, blood, nasal epithelial cells, placenta and skin, have the capacity to metabolize peptides. We compared the metabolic characteristics of peptides in these tissues and then summarized strategies for improving peptide stability.
Results: In addition to the primary organs including liver, kidney, gastrointestinal tract and blood involved in peptide metabolism, other organs such as the lung, skin, placenta and nasal mucosa may also play a role in peptide degradation. At present, the main measures to improve the stability of the peptide include N- and/or C-terminal modification or substitution, D-amino acid or unnatural amino acid substitution, cyclization, backbone modification, nanoparticle formulations and increased molecular mass.
Conclusion: This review summarized the key in vivo peptidases and their tissue distribution characteristics, and presented strategies to improve the metabolic stability and bioavailability of peptide drugs. These viewpoints will benefit the further development and utilization of peptide drugs.
Export Options
About this article
Cite this article as:
Yao Jin-Feng , Yang Hong , Zhao Yan-Zhi and Xue Ming *, Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability, Current Drug Metabolism 2018; 19 (11) . https://dx.doi.org/10.2174/1389200219666180628171531
| DOI https://dx.doi.org/10.2174/1389200219666180628171531 |
Print ISSN 1389-2002 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Impact of Brain Tissue Binding and Plasma Protein Binding of Drugs in DMPK
The impression of brain tissue binding (BTB) or plasma protein binding (PPB) in Drug Metabolism and Pharmacokinetics is critical to understanding the distribution, efficacy, and potential toxicity of drugs that target the central nervous system (CNS). BTB and high PPB influence the distribution of drugs in the body and their ...read more
Innovative Therapeutic Approaches in Infectious Diseases
Infectious diseases continue to challenge global health systems due to rising antimicrobial resistance, emerging pathogens, and increasing drug tolerance. This special issue aims to move beyond traditional approaches by exploring innovative pharmacological strategies for the treatment of infectious diseases. We welcome original research and reviews ranging from clinical trials and ...read more
Interaction Between Drugs and Endocrine Diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Metabolism-Mediated Xenobiotic Toxicity
Considering the potent modulation of biotransformation enzyme expression and activities by various therapeutic drugs and environmental chemicals, and the commonly combined exposure of humans to both drugs and the ever increasing environmental pollutants simultaneously, knowledge about the combined toxic effects by modulating biotransformation enzymes, such as P450s, UDP- glucuronosyltransferases, and ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease
Current Medicinal Chemistry The Novel Multi-Target Iron Chelator, M30 Modulates HIF-1α-Related Glycolytic Genes and Insulin Signaling Pathway in the Frontal Cortex of APP/PS1 Alzheimer’s Disease Mice
Current Alzheimer Research Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Activity-Based Proteomics of Lipolytic Enzymes
Current Drug Discovery Technologies Multi-Target Strategy and Experimental Studies of Traditional Chinese Medicine for Alzheimer’s Disease Therapy
Current Topics in Medicinal Chemistry Physiological Proteins in Therapeutics: A Current Review on Interferons
Mini-Reviews in Medicinal Chemistry Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma
Current Drug Targets Grape Phytochemicals and Vitamin D in the Alleviation of Lung Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Hydroxychloroquine Sulfate (Plaquenil): A Possible Candidate for Pandemic SARS-CoV-2 or (COVID-19) ?
Coronaviruses Non-coding RNAs in Regulation of Protein Aggregation and Clearance Pathways: Current Perspectives Towards Alzheimer's Research and Therapy
Current Gene Therapy Immunophenotype of Vitamin D Receptor Polymorphism Associated to Risk of HIV-1 Infection and Rate of Disease Progression
Current HIV Research Swimming Activity and Non-Protein Energy (NPE) Metabolism in Fish
Current Nutrition & Food Science Role of Defensins and Cathelicidin LL37 in Auto-Immune and Auto- Inflammatory Diseases
Current Pharmaceutical Biotechnology Fcγ Receptor 1 (CD64), a Target Beyond Cancer
Current Pharmaceutical Design Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Regulation of NF-κB signalling cascade by immunophilins
Current Molecular Pharmacology Development and Organization of the Secondary and Tertiary Lymphoid Organs: Influence of Microbial and Food Antigens
Endocrine, Metabolic & Immune Disorders - Drug Targets Plasmid-Based Expression Technology Using Growth Hormone Releasing Hormone: A Novel Method for Physiologically Stimulating Long-Term Growth Hormone Secretion
Combinatorial Chemistry & High Throughput Screening Predicted SARS-CoV-2 miRNAs Associated with Epigenetic Viral Pathogenesis and the Detection of New Possible Drugs for Covid-19
Current Drug Delivery AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets





